Gilead Sciences, Inc.
GILD
$125.00
$1.090.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.09B | 28.86B | 28.73B | 28.75B | 28.30B |
| Total Other Revenue | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Revenue | 29.09B | 28.86B | 28.74B | 28.75B | 28.30B |
| Cost of Revenue | 6.19B | 6.20B | 6.24B | 6.25B | 6.28B |
| Gross Profit | 22.90B | 22.67B | 22.50B | 22.50B | 22.02B |
| SG&A Expenses | 5.79B | 5.85B | 5.86B | 6.00B | 5.72B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.72B | 17.83B | 17.79B | 18.07B | 17.66B |
| Operating Income | 11.37B | 11.03B | 10.95B | 10.69B | 10.64B |
| Income Before Tax | 9.89B | 7.20B | 6.83B | 691.00M | 177.00M |
| Income Tax Expenses | 1.78B | 890.00M | 860.00M | 211.00M | 63.00M |
| Earnings from Continuing Operations | 8.11K | 6.31K | 5.97K | 480.00 | 114.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 12.00M |
| Net Income | 8.11B | 6.31B | 5.97B | 480.00M | 126.00M |
| EBIT | 11.37B | 11.03B | 10.95B | 10.69B | 10.64B |
| EBITDA | 14.13B | 13.80B | 13.72B | 13.45B | 13.41B |
| EPS Basic | 6.51 | 5.06 | 4.78 | 0.38 | 0.10 |
| Normalized Basic EPS | 5.37 | 5.18 | 5.13 | 5.01 | 5.00 |
| EPS Diluted | 6.44 | 5.01 | 4.74 | 0.35 | 0.08 |
| Normalized Diluted EPS | 5.32 | 5.14 | 5.10 | 4.99 | 4.98 |
| Average Basic Shares Outstanding | 4.98B | 4.99B | 4.99B | 4.99B | 4.99B |
| Average Diluted Shares Outstanding | 5.03B | 5.03B | 5.02B | 5.01B | 5.01B |
| Dividend Per Share | 3.14 | 3.12 | 3.10 | 3.08 | 3.06 |
| Payout Ratio | 49.10% | 62.75% | 66.02% | 816.25% | 3,085.71% |